Chemerin15
Based on 1 Customer Validation
Chemerin15 is an anti-inflammatory peptide derived from Chemerin. Chemerin15 binds to ChemR23. Chemerin15 inhibits TNFα-induced activation of Syk, ERK and Src kinases. Chemerin15 increases the expression of p-p38 mRNA and protein. Chemerin15 mediates phagocytosis, resolution of inflammation, CD62L shedding and downregulation of PSGL-1 expression in macrophages and microglia. Chemerin15 inhibits neutrophil-mediated vascular inflammation and myocardial ischemia-reperfusion injury via ChemR23. Chemerin15 enhances microglial phagocytosis, thereby alleviating cerebral ischemia-reperfusion injury.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 99.65%
- CAS No.: 1020407-90-2
- 화학식: C75H100N18O22
- 분자량:1605.70
-
보관:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
용액&용해도
- 순도&문서
- References
-
Help & FAQs
All Chemerin Receptor Isoforms
More
Biological Activity
Chemerin15 (0.1 pM-1 nM; 45 min) enhances the phagocytic rate and capacity of wild-type mouse peritoneal macrophages against zymosan and opsonized zymosan in vitro in a ChemR23- and Syk-dependent manner, with its optimal active concentration being 10 pM[1].
Chemerin15 (0.01 pM-10 pM; 45 min) enhances the non-inflammatory phagocytosis of apoptotic Jurkat cells by peritoneal macrophages from wild-type mice, with an optimal active concentration of 1 pM[1].
Chemerin15 (500 ng/mL; 30 min) enhances the phagocytosis of pHrodo Red Zymosan bioparticles by OGD-treated BV2 mouse microglia via the ChemR23 receptor[2].
Chemerin15 (500 ng/mL; 30 min) promotes phagocytosis of HT-22 mouse hippocampal neurons by OGD-treated RFP-BV2 mouse microglia[2].
Chemerin15 (500 ng/mL; 30 min) upregulates phagocytosis-related genes and activates the p38 MAPK signaling pathway in OGD-treated BV2 mouse microglia via the ChemR23 receptor[2].
Chemerin15 (500 ng/mL; 30 min) upregulates the expression of phosphorylated p38 MAPK protein in OGD-treated BV2 mouse microglial cells via the ChemR23 receptor[2].
Chemerin15 (0.1-1000 pM; 20 min) induces CD62L shedding and reduces PSGL-1 expression in human resting neutrophils, with 10 pM Chemerin15 causing 50% CD62L shedding and a 25% downregulation of PSGL-1 expression[3].
Chemerin15 (10-1000 pM; 10 min) inhibits TNFα-induced adhesion and spreading of human neutrophils to immobilized ICAM-1 via a ChemR23-dependent mechanism, with an inhibition rate of 65% at 10 pM[3].
Chemerin15 (10 pM) inhibits TNFα-induced activation of Syk, ERK and Src kinases in human neutrophils, with inhibition rates of 69%, 80% and 61% on pSyk, pErk and pSrc activities, respectively[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:BV2 mouse microglial cells
-
Concentration:500 ng/mL
-
Incubation Time:30 min (pre-incubated before OGD)
-
Result:Significantly increased both p-p38 mRNA and protein expression in BV2 cells compared to the OGD-only group.
Inhibited the increase in p-p38 expression when co-treated with α-NETA, reducing levels toward those seen in the OGD-only group.
Chemerin15 (0.3 ng/kg; intranasal; after reperfusion) enhances microglial phagocytosis, reduces DAMP and ROS levels, decreases infarct volume by ~40%, and improves neurological function in mice with cerebral ischemia-reperfusion injury via the ChemR23/p38 MAPK pathway[2].
Chemerin15 (0.1-100 pg/mouse; i.p., i.v.) inhibits TNFα-induced mesenteric microvascular inflammation in mice through ChemR23, with prophylactic administration reducing neutrophil adhesion by 70% and extravasation by 60% at 10 pg/mouse, and therapeutic administration causing ~50% detachment of adherent neutrophils within 3.4 minutes[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6J mice (zymosan-induced peritonitis)[1]
-
Dosage:8 pg/mouse (0.32 ng/kg)
-
Administration:i.p.; single dose
-
Result:Enhanced macrophage zymosan clearance by 38% at 1 hour post-zymosan challenge, increasing the percentage of zymosan+F4/80+ peritoneal exudate cells from 23% to 34%; enhanced clearance was also observed at 2 and 4 hours.
Enhanced Ly6G+ apoptotic neutrophil phagocytosis by 88% at 8 hours post-zymosan challenge, with enhanced clearance also seen at 2, 4, and 16 hours.
Reduced the percentage of apoptotic peritoneal exudate cells by 31% (from 18% to 12%) and necrotic cells by 53% (from 4% to 1.9%) at 4 hours post-zymosan challenge.
-
Animal Model:C57Bl/6J mice; Sv129Ev wild-type mice; Sv129Ev ChemR23 - / - mice (vascular inflammation induced by intraperitoneal TNFα)[3]
-
Dosage:0.1 pg/mouse; 10 pg/mouse; 100 pg/mouse
-
Administration:i.p. (prophylactic); i.v. (therapeutic)
-
Result:Increased leukocyte rolling velocities fourfold, reduced neutrophil adhesion by 70%, and reduced neutrophil extravasation by 60% at 10 pg/mouse (prophylactic).
Elicited rapid detachment of ~50% of adherent neutrophils from inflamed venular endothelium, with an average onset of 3.4 minutes post-injection at 10 pg/mouse (therapeutic).
Showed maximal efficacy at 10 pg/mouse and 100 pg/mouse (prophylactic).
Accelerated return to baseline rolling velocities while reducing adhesion and emigration (prophylactic).
No effects were observed in ChemR23 - / - mice.
Chemical Information
-
CAS No. 1020407-90-2
-
Appearance Solid
-
분자량 1605.70
-
화학식 C75H100N18O22
-
Color White to off-white
-
Sequence
Ala-Gly-Glu-Asp-Pro-His-Gly-Tyr-Phe-Leu-Pro-Gly-Gln-Phe-Ala
-
Sequence Shortening
AGEDPHGYFLPGQFA
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
용액&용해도
DMSO : 100 mg/mL (62.28 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
순도&문서
-
Data Sheet (284 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Cash JL, et al. Chemerin peptides promote phagocytosis in a ChemR23- and Syk-dependent manner. J Immunol. 2010;184(9):5315-5324. [Content Brief]
[2]. Yang Y, et al. Chemerin 15 enhances microglial phagocytosis to attenuate cerebral ischemia-reperfusion injury through the ChemR23/p38 MAPK pathway. iScience. 2025;28(9):113396. Published 2025 Aug 19. [Content Brief]
[3]. Cash JL, et al. Chemerin15 inhibits neutrophil-mediated vascular inflammation and myocardial ischemia-reperfusion injury through ChemR23. EMBO Rep. 2013;14(11):999-1007. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 0.6228 mL | 3.1139 mL | 6.2278 mL | 15.5695 mL |
| 5 mM | 0.1246 mL | 0.6228 mL | 1.2456 mL | 3.1139 mL | |
| 10 mM | 0.0623 mL | 0.3114 mL | 0.6228 mL | 1.5570 mL | |
| 15 mM | 0.0415 mL | 0.2076 mL | 0.4152 mL | 1.0380 mL | |
| 20 mM | 0.0311 mL | 0.1557 mL | 0.3114 mL | 0.7785 mL | |
| 25 mM | 0.0249 mL | 0.1246 mL | 0.2491 mL | 0.6228 mL | |
| 30 mM | 0.0208 mL | 0.1038 mL | 0.2076 mL | 0.5190 mL | |
| 40 mM | 0.0156 mL | 0.0778 mL | 0.1557 mL | 0.3892 mL | |
| 50 mM | 0.0125 mL | 0.0623 mL | 0.1246 mL | 0.3114 mL | |
| 60 mM | 0.0104 mL | 0.0519 mL | 0.1038 mL | 0.2595 mL |
Chemerin15 Related Classifications
HY-P6442 Related Classifications
Powered by Bioz